Officials with The Medicines Company announced the launch of a new formulation of minocycline (Minocin for Injection). Minocin for Injection is indicated for the treatment of infections due to susceptible strains of designated bacteria, including the Acinetobacter species.
The new formulation contains magnesium sulfate, an excipient, which allows for administration at a more physiologic pH. The dosing remains the same as the prior Minocin for Injection but the new formulation can be administered in volumes as low as 100mL vs. the 500–1000mL in the older formulation.
Minocin is a tetracycline antibiotic that is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. Tetracyclines, including minocycline, have a similar antimicrobial spectrum of activity against a wide range of Gram-positive and Gram-negative bacteria.
Minocin for Injection is available as 100 mg vials. The Medicines Company ceased manufacturing and sales of the old formulation on July 17, 2015. The Company will dispose any returned old formulation and issue a credit to the wholesaler.
For more information call (888) 977-6326 or visit MinocinIV.com.
This article originally appeared on MPR